NMS·Healthcare·$620M·#188 / 520 in Healthcare
RGNX REGENXBIO Inc.
54SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY74
STABILITY16
VALUATION60
GOVERNANCE33
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+104.5%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
88.1%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
3 months
6
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
71.5%
36
< 25% strong
Price / Sales
Market cap relative to trailing revenue
7.1x
60
< 3x strong
Rule of 40
Growth rate plus operating margin
10
35
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
6.6%
48
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+27.1%
3
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE RGNX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when RGNX's score changes by 5+ points.
DATA INFO
Last updated: Aug 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.